More than 50% of patients treated with Opdivo plus Yervoy were alive at four years
Patients who received Opdivo plus Yervoy maintained durable responses, with the combination showing improved duration of response vs. sunitinib
Updated results from the Phase 3 CheckMate -214 trial, presented at the European Society for Medical Oncology Virtual Congress 2020, represent longest follow-up by nearly two years of any immunotherapy combination in first-line renal cell carcinoma
San Francisco, CA (UroToday.com) — Bristol Myers Squibb announced that more than half of advanced renal cell carcinoma (RCC) patients treated with the Opdivo®(nivolumab)plus Yervoy®(ipilimumab)combination were alive after four years across the entire study population of the Phase 3 CheckMate -214 clinical trial. With the longest follow-up for an immunotherapy-based combination in previously untreated advanced RCC, Opdivo plus Yervoy continued to show superior, long-term overall survival (OS) and durable responses compared to sunitinib. These sustained benefits were observed across both the primary patient population, those with intermediate- and poor-risk prognostic factors, and in the intention-to-treat (ITT, i.e. all randomized) patient population.